OTCMKTS:WUXIF

WuXi AppTec Competitors

$19.88
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.88
Now: $19.88
$19.88
50-Day Range
$14.80
MA: $17.58
$19.88
52-Week Range
$9.29
Now: $19.88
$19.88
VolumeN/A
Average Volume1,125 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

WuXi AppTec (OTCMKTS:WUXIF) Vs. OLK, OCDX, BDSX, LHDX, NOTV, and AKU

Should you be buying WUXIF stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to WuXi AppTec, including Olink Holding AB (publ) (OLK), Ortho Clinical Diagnostics (OCDX), Biodesix (BDSX), Lucira Health (LHDX), Inotiv (NOTV), and Akumin (AKU).

Olink Holding AB (publ) (NASDAQ:OLK) and WuXi AppTec (OTCMKTS:WUXIF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares Olink Holding AB (publ) and WuXi AppTec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Olink Holding AB (publ)N/AN/AN/A
WuXi AppTecN/AN/AN/A

Valuation and Earnings

This table compares Olink Holding AB (publ) and WuXi AppTec's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olink Holding AB (publ)N/AN/AN/AN/AN/A
WuXi AppTecN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Olink Holding AB (publ) and WuXi AppTec, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Olink Holding AB (publ)0000N/A
WuXi AppTec00103.00

Summary

WuXi AppTec beats Olink Holding AB (publ) on 1 of the 1 factors compared between the two stocks.

Ortho Clinical Diagnostics (NASDAQ:OCDX) and WuXi AppTec (OTCMKTS:WUXIF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Ortho Clinical Diagnostics and WuXi AppTec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ortho Clinical DiagnosticsN/AN/AN/A
WuXi AppTecN/AN/AN/A

Earnings & Valuation

This table compares Ortho Clinical Diagnostics and WuXi AppTec's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ortho Clinical DiagnosticsN/AN/AN/AN/AN/A
WuXi AppTecN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Ortho Clinical Diagnostics and WuXi AppTec, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ortho Clinical Diagnostics011102.92
WuXi AppTec00103.00

Ortho Clinical Diagnostics presently has a consensus target price of $24.2727, indicating a potential upside of 30.99%. Given Ortho Clinical Diagnostics' higher probable upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than WuXi AppTec.

Summary

Ortho Clinical Diagnostics beats WuXi AppTec on 2 of the 3 factors compared between the two stocks.

Biodesix (NASDAQ:BDSX) and WuXi AppTec (OTCMKTS:WUXIF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Biodesix and WuXi AppTec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiodesixN/AN/AN/A
WuXi AppTecN/AN/AN/A

Earnings & Valuation

This table compares Biodesix and WuXi AppTec's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiodesixN/AN/AN/AN/AN/A
WuXi AppTecN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Biodesix and WuXi AppTec, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biodesix00403.00
WuXi AppTec00103.00

Biodesix presently has a consensus target price of $26.00, indicating a potential upside of 34.23%. Given Biodesix's higher probable upside, analysts clearly believe Biodesix is more favorable than WuXi AppTec.

Summary

Biodesix beats WuXi AppTec on 2 of the 2 factors compared between the two stocks.

WuXi AppTec (OTCMKTS:WUXIF) and Lucira Health (NASDAQ:LHDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares WuXi AppTec and Lucira Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WuXi AppTecN/AN/AN/A
Lucira HealthN/AN/AN/A

Valuation and Earnings

This table compares WuXi AppTec and Lucira Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WuXi AppTecN/AN/AN/AN/AN/A
Lucira HealthN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for WuXi AppTec and Lucira Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WuXi AppTec00103.00
Lucira Health10202.33

Lucira Health has a consensus target price of $9.00, indicating a potential upside of 14.80%. Given Lucira Health's higher probable upside, analysts plainly believe Lucira Health is more favorable than WuXi AppTec.

Summary

Lucira Health beats WuXi AppTec on 2 of the 3 factors compared between the two stocks.

WuXi AppTec (OTCMKTS:WUXIF) and Inotiv (NASDAQ:NOTV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for WuXi AppTec and Inotiv, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WuXi AppTec00103.00
Inotiv0000N/A

Profitability

This table compares WuXi AppTec and Inotiv's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WuXi AppTecN/AN/AN/A
InotivN/AN/AN/A

Valuation and Earnings

This table compares WuXi AppTec and Inotiv's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WuXi AppTecN/AN/AN/AN/AN/A
InotivN/AN/AN/AN/AN/A

Summary

WuXi AppTec beats Inotiv on 1 of the 1 factors compared between the two stocks.

Akumin (NASDAQ:AKU) and WuXi AppTec (OTCMKTS:WUXIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings & Valuation

This table compares Akumin and WuXi AppTec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminN/AN/AN/AN/AN/A
WuXi AppTecN/AN/AN/AN/AN/A

Profitability

This table compares Akumin and WuXi AppTec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
WuXi AppTecN/AN/AN/A

Institutional and Insider Ownership

30.4% of Akumin shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Akumin and WuXi AppTec, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin00103.00
WuXi AppTec00103.00

Summary

Akumin beats WuXi AppTec on 1 of the 1 factors compared between the two stocks.


WuXi AppTec Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
OLK
Olink Holding AB (publ)
0.0$37.50flat$4.46 billionN/A0.00
Ortho Clinical Diagnostics logo
OCDX
Ortho Clinical Diagnostics
1.8$18.53flat$4.12 billionN/A0.00
Biodesix logo
BDSX
Biodesix
1.6$19.37flat$514.82 millionN/A0.00
Lucira Health logo
LHDX
Lucira Health
1.3$7.84flat$302.11 millionN/A0.00Analyst Downgrade
Analyst Revision
NOTV
Inotiv
0.0$22.50flat$250.45 millionN/A0.00Analyst Downgrade
News Coverage
Gap Up
Akumin logo
AKU
Akumin
0.6$3.07flat$215.45 millionN/A0.00Analyst Upgrade
Relay Medical logo
RYMDF
Relay Medical
0.0$0.39flat$57.07 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Global WholeHealth Partners logo
GWHP
Global WholeHealth Partners
0.0$0.69flat$46.58 millionN/A0.00Gap Down
Epigenomics logo
EPGNY
Epigenomics
0.6$12.39flat$0.00N/A0.00Increase in Short Interest
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00News Coverage
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00Gap Down
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.